1. Главная
  2. Ресурсы
  3. Библиотечный поиск
Multitarget Therapy:An Effective and SafeTherapeutic Regimenfor Lupus Nephritis Tian‐Biao ZhouXialan ZhangWenshan Lin2019 год

Multitarget Therapy: An Effective and Safe Therapeutic Regimen for Lupus Nephritis
статья из журнала

Полный текстСтраница публикацииПубликация в OpenAlex
Аннотация: Introduction: We evaluated the effectiveness and safety of various multitarget therapies for inducing remission in lupus nephritis patients. Methods: Randomized controlled trials (RCT) were identified and extracted from the Embase, PubMed, Chinese Biomedical Literature Database (CBM), and the Cochrane Library until Oct 31, 2018, investigations meeting inclusion criteria were extracted, and data were analyzed by meta-analysis. The total remission (TR; complete to partial remission), complete remission (CR), albumin, proteinuria levels, negative rate of anti-double-stranded DNA antibody (ds-DNA), negative rate of anti-nuclear antibody (ANA), and systemic lupus erythematosus disease activity index (SLE-DAI) were calculated using the software of RevMan 5.3. Results: Eleven RCTs were included and analyzed. The multitarget therapy group exhibited a higher value of CR (OR=3.06, 95%CI: 2.35-3.99, P﹤0.00001) as well as TR (OR=3.83, 95%CI: 2.77-5.31, P﹤0.00001) than those in the cyclophosphamide (CYC) group. In addition, multitarget therapies had more albumin (WMD=3.50, 95%CI: 1.04-5.95, P=0.005), greater albumin increases (OR=1.96, 95%CI: 0.63-3.29, P=0.004) and higher negative rates of ds-DNA (OR=2.13, 95%CI: 1.51-3.01, P﹤0.0001) and ANA (OR=2.82, 95%CI: 1.77-4.50, P﹤0.0001) when compared with the CYC group. This group also had less proteinuria levels (WMD=-0.55, 95%CI: -0.79 to -0.30, P﹤0.0001), lower degrees of SLE-DAI (OR=-1.80, 95%CI:-2.78 to -0.81, P=0.0004), and a lower adverse reaction rate. For example, gastrointestinal syndrome, irregular menstruation and leucopenia happened less frequently in the multitarget therapy group. However, hypertension was more prevalent in the multitarget therapy group. Conclusions: Multitarget therapy is an effective and safe intervention for inducing remission in lupus nephritis patients.
Год издания: 2019
Авторы: Tian‐Biao Zhou, Xialan Zhang, Wenshan Lin, Shujun Lin
Издательство: Canadian Society for Pharmaceutical Sciences
Источник: Journal of Pharmacy & Pharmaceutical Sciences
Ключевые слова: Systemic Lupus Erythematosus Research, Renal Diseases and Glomerulopathies, Monoclonal and Polyclonal Antibodies Research
Другие ссылки: Journal of Pharmacy & Pharmaceutical Sciences (PDF)
Journal of Pharmacy & Pharmaceutical Sciences (HTML)
DOAJ (DOAJ: Directory of Open Access Journals) (HTML)
PubMed (HTML)